Solstein Capital’s Amedisys AMED Stock Holding History

Solstein Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-16	Closed	-$4K	–	461
2021 Q2	$4K	Hold	16	–	–	﹤0.01%	391
2021 Q1	$4K	Buy	+16	New	+$4.51K	0.01%	351

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Solstein Capital's AMED Position: Q3 2021 in Review

Solstein Capital sold out of Amedisys (AMED) in Q3 2021, closing a stake of 16 shares — an estimated $4K sold.

Solstein Capital first reported a position in AMED in Q1 2021 and held it in 2 quarters. The position peaked at $4K in Q2 2021. 351 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

Solstein Capital reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
Solstein Capital sold 16 Amedisys shares in Q3 2021, an estimated $4K.
Solstein Capital first reported a position in Amedisys in Q1 2021 and held it in 2 quarters.
Solstein Capital's Amedisys position peaked at $4K in Q2 2021.
351 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on Solstein Capital's 13F filing for Q3 2021, filed 27 Oct 2021.